Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET

Company Participants

Julie Burek - Vice President of Finance

Dr. Al Sandrock - Chief Financial Officer

Dr. Todd Carter - Senior Vice President of Research

Conference Call Participants

Jack Allen - Baird

Divya Rao - Cowen & Company

Yung Zhong - BTIG

Operator

Good day, and welcome to Voyager Therapeutics Second Quarter 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call which will be recorded. [Operator Instructions]

I would now like to turn the call over to Julie Burek Vice President of Finance at Voyager.

Julie Burek

Thank you, operator. Good afternoon, everyone, and welcome to this conference call to discuss our second quarter 2022 results and prioritized pipeline. A replay of today's call, including the Q&A, will be available on the Investors section of our website approximately two hours after completion of this call. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC and as updated by our subsequent filings.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements even if our views change.

I'm joined today by our Chief Executive Officer, Dr. Al Sandrock. For the Q&A portion of the call, we will be joined by our Senior Vice President of Research, Dr. Todd Carter.

Now I will turn the call over to Al.

Dr. Al Sandrock

Thanks, Julie, and good afternoon, everyone. I'm extremely pleased to discuss some exciting new developments at Voyager. Voyager's mission is to pioneer the discovery of transformational AAV capsids that we hope will enable the development of life-changing gene therapies. We believe that the novel capsids derived from our proprietary tracer platform represent the breakthrough innovation that will address certain fundamental limitations that currently hamper gene therapy. We and our partners plan to leverage these capsids to advance the field of gene therapy for the central nervous system as well as other organs.